Physician profile
Julia Marki
NPI 1093226524
$3,772.79
in general payments reported to CMS, 2019-2025
29 companies · $843 in 2025
The $843 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $1,186 · 2023: $731 · 2024: $497 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057 · Education: $13.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.45 |
| Education | $13.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,027.16 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Vectris Surescan |
| Collegium Pharmaceutical, INC. | $940.89 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.00 | 2021-2025 | Relistor |
| Grt US Holding, INC. | $209.50 | 2021-2022 | |
| Si-Bone, INC. | $143.72 | 2022-2025 | |
| Boston Scientific Corporation | $120.61 | 2022 | |
| Redhill Biopharma INC. | $101.19 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $101.02 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $94.88 | 2024-2025 | |
| Ibsa Pharma INC. | $84.08 | 2022-2023 | Tirosint, Licart |
| Virtus Pharmaceuticals LLC | $60.65 | 2023-2024 | Levorphanol Tartrate |
| Abbott Laboratories | $47.01 | 2022-2023 | Proclaim |
| Averitas Pharma INC. | $46.00 | 2023 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $45.06 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $43.38 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $40.58 | 2023-2024 | Horizant, Horizant |
| Amneal Pharmaceuticals LLC | $40.38 | 2023 | Lyvispah |
| Forte Bio-Pharma LLC | $38.80 | 2022-2025 | Prolate, Tanlor, Nalocet |
| Almatica Pharma LLC | $38.35 | 2022-2024 | Teriparatide |
| Curonix LLC | $32.44 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertos Medical, INC. | $29.25 | 2023 | Mild Device Kit |
| Saluda Medical Americas, INC. | $25.53 | 2025 | Evoke |
| Abbvie INC. | $24.03 | 2021 | |
| Avanos Medical | $21.10 | 2024 | Standard Rf Disposables |
| Bioventus LLC | $20.30 | 2025 | Xcell |
| Vanda Pharmaceuticals INC. | $19.61 | 2025 | Fanapt, Hetlioz |
| Protega Pharmaceutials INC | $18.22 | 2025 | Roxybond |
| Nalu Medical, INC. | $18.21 | 2023 | Nalu Neurostimulation System |
| Novo Nordisk INC | $17.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Marki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.